Through our in vivo challenge experiments, we initially found that CXCR3 deficiency resulted in delayed body weight recovery and higher brain parasite burden in the mice, implying that this deficiency exacerbated clinical disease during the sub-acute (15–30 dpi) to chronic phases (30–60 dpi) of infection. Here, CXCR3 is linked to infection.